Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a few weeks of radiation be enough for recurrent prostate cancer?

NCT ID NCT03388619

First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 25 times

Summary

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumor seen on scans. The goal was to find the shortest schedule that men could tolerate without serious side effects. 30 men participated, and the study is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radiation therapy

What this could lead to

If successful, this could lead to a shorter, more convenient radiation schedule for men whose prostate cancer returns after surgery, with fewer side effects.

What could go wrong

This is a very early phase 1 trial with only 30 participants, so it is not yet clear if the shorter schedule is as effective as the standard longer one. Side effects are still being studied.

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.